Universal reference book for medicines

Active substance: measles vaccine (live)

Type: Vaccine for measles prevention

Manufacturer: SERUM INSTITUTE OF INDIA (India)
Composition, form of production and packaging
Lyophilizate for the preparation of a solution for p / c injection
in the form of a homogeneous porous, loose mass, white or white and yellow, hygroscopic.

1 dose (0.5 ml)

measles virus not less than 1 000 TCD 50

Excipients: stabilizer - sorbitol - 25 mg, gelatin - 12.5 mg.

1 dose - bottles (50) complete with a solvent (amp 0.5 ml) - packs of cardboard.

10 doses - bottles (50) complete with a solvent (amp 5 ml) - packs of cardboard.


Description of the drug approved by the manufacturer for the printed edition of 2011.


The vaccine stimulates the production of antibodies to the measles virus, which reach a maximum level 3-4 weeks after vaccination.

The drug meets WHO requirements.


- routine measles prophylaxis.

Routine vaccinations are carried out twice at the age of 12-15 months and 6 years for children who do not have measles.

Children born from seronegative measles virus to the virus are vaccinated at the age of 8 months and further - at 14-15 months and 6 years.

The interval between vaccination and re-vaccination should be at least 6 months.


Immediately before use, the vaccine is diluted with only the applied solvent (water for injection) using a sterile syringe at a rate of 0.5 ml of solvent per vaccination dose of the vaccine.

The vaccine should completely dissolve within 3 minutes to form a clear, colorless or pale yellow solution.

Vaccine and solvent in vials and ampoules with broken integrity, marking, as well as changing their physical properties (color, transparency, etc.), expired, improperly stored, are not suitable for use.

Opening of vials, ampoules and vaccination procedure is carried out with strict adherence to aseptic and antiseptic rules.
Ampoule at the incision site is treated with 70 ° alcohol and break, while not allowing the ingress of alcohol into the ampoule.
To dilute the vaccine with a sterile syringe, take out all the necessary volume of the solvent and transfer it to a bottle with a dry vaccine.
After mixing, the needle is changed, the vaccine is taken into the syringe and injected.
The vaccine is injected deep in the subcutaneous volume in the volume of 0.5 ml under the shoulder blade or in the shoulder region (on the border between the lower and middle third of the shoulder from the outside), pretreating the skin at the site of administration of the vaccine with 70 ° alcohol.

The diluted vaccine is not subject to storage.

The accompanying solvent is specially formulated for this vaccine.
It is not allowed to use solvents for other vaccines and for measles vaccines of other manufacturers. The use of inappropriate solvents can lead to a change in the properties of the vaccine and severe reactions in recipients.

In the next 24 hours after the introduction of the measles vaccine, moderate pain may occur at the injection site.
In most cases, the pain passes for 2-3 days without treatment. 5-15% of those vaccinated on the 7-12th day after vaccination may have a mild temperature increase of 1-2 days. In 2% of those vaccinated on the 7-10th day after the vaccination, a rash of up to 2 days may develop.
Moderate adverse reactions occur less frequently after the second dose of the vaccine.
In the post-vaccination period, encephalitis was registered at a frequency of 1: 1,000,000 doses administered, with no causal relationship with vaccination proven.
Complications that develop extremely rarely include convulsive reactions that occur most often 6-10 days after vaccination, usually against a high temperature, and allergic reactions that occur in the first 24-48 hours in children with allergic reactivity.

A rise in temperature above 38.5 ° C in the post-vaccination period is an indication for the appointment of antipyretics.


- primary immunodeficiency states, malignant blood diseases and neoplasms;

- a strong reaction (temperature rise above 40 ° C, edema, hyperemia more than 8 cm in diameter at the site of injection) or complication of previous administration of the vaccine;

- severe renal dysfunction;

- heart disease in the stage of decompensation;

- Pregnancy.


Contraindicated in pregnancy.


Contraindicated in severe renal dysfunction;


Vaccinations are conducted:

- after acute infectious and non-infectious diseases, with exacerbation of chronic diseases - at the end of acute manifestations of the disease;

- with non-severe forms of acute respiratory viral infection, acute intestinal diseases and others - immediately after the normalization of temperature;

- after immunosuppressive therapy - 3-6 months after the end of treatment.

Persons temporarily released from vaccinations should be monitored and vaccinated after withdrawal of contraindications.

When a vaccine is administered to patients receiving corticosteroids, immunosuppressive drugs or undergoing radiotherapy, an adequate immune response may not be obtained.

A vaccine can be given to children with an established or suspected HIV infection.
Although the available data are insufficient and additional studies are required, there is currently no evidence of a greater incidence of adverse reactions when this vaccine or other measles vaccines are administered to children with clinical or asymptomatic HIV infection. The vaccine should not be administered in other immunodeficient conditions with a violation of cellular immunity.
The vaccine should only be administered subcutaneously.
Vaccinated should be under medical supervision for at least 30 minutes after immunization. Places of vaccination should be equipped with anti-shock therapy. To stop anaphylactic reactions that may occur in children with allergic reactivity to the introduction of not only the measles vaccine, but also other vaccines, you should have a 1: 1000 adrenaline solution ready. Injection of adrenaline should be made at the first suspicion of the onset of development of shock reaction.

After the administration of human immunoglobulin preparations, measles vaccines are given no earlier than 2 months.
After the introduction of measles vaccine, immunoglobulin preparations can be administered no earlier than 2 weeks later; If immunoglobulin is required before this time, measles vaccination should be repeated.
After vaccination, there may be a transient inversion of the tuberculin-positive reaction to the tuberculin-negative reaction.

Vaccination against measles can be done simultaneously (on the same day) with other immunizations of the National calendar (against mumps, rubella, poliomyelitis, hepatitis B, pertussis, diphtheria, tetanus) or not earlier than 1 month after the previous vaccination.


For treatment-and-prophylactic and sanitary-preventive institutions


Storage: vaccines - at a temperature of 2 ° C to 8 ° C in a dark place out of the reach of children;
at a temperature of 5 ° C to 30 ° C. Do not freeze.
Transport of vaccine and solvent: at a temperature of 2 ° C to 8 ° C.

Shelf life of the vaccine is 2 years, the solvent is 5 years.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!